73 results about "Glucose management" patented technology

The invention relates to the technical field of medical care informatization, in particular to a diabetes and early-stage patient self-management system based on AI and CGM, which comprises the following steps: carrying out delayed alignment on CGM blood glucose flow and multi-modal physiological signals through a signal acquisition and synchronization module; an intelligent event triggering module is used for dynamically adjusting a triggering threshold value for different disease course stages so as to identify suspected events; a mixed consistency verification engine is combined with a medical prior rule and an ensemble classification model to carry out joint discrimination, and a consistency probability is output; and the individual parameters are optimized in cooperation with a hierarchical decision-making mechanism of the interaction module and online incremental learning of the adaptive learning module. Therefore, frequent false alarms caused by physical limitations such as inherent physiological delay and signal drifting of a CGM sensor and alarm fatigue and decline of compliance of a patient caused by the frequent false alarms are solved, and more stable and personalized dynamic blood glucose management support is provided for active people in the early stage of diabetes mellitus and the like.

The invention relates to the technical field of intelligent medical monitoring, and discloses a critical patient blood glucose monitoring and risk intervention system based on artificial intelligence. The system comprises a multi-source physiological data integration module, a risk map construction module, an intervention decision generation module and an intervention execution control module. The system integrates and standardizes physiological data from the continuous blood glucose monitor and the multi-parameter monitoring equipment; the physiological parameters are mapped into pathological nodes based on the medical knowledge map, and the activation probability of the pathological nodes is calculated to construct an individualized risk map, so that systematic risk assessment is realized. Further, in combination with individual information of the patient, performing multi-objective optimization on the intervention strategy by applying a simulated annealing algorithm to generate an optimal decision; and analyzing the decision into a control instruction to drive the insulin pump to execute precise intervention. According to the invention, the crossing from passive alarm to active risk prediction and personalized intervention is realized, and the safety and accuracy of blood glucose management of critical patients are improved.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention relates to the technical field of intelligent diabetes treatment instruments, in particular to a closed-loop non-invasive insulin detection and precise infusion system which is characterized by comprising a blood glucose monitoring regulator, a non-invasive injector and a closed-loop control mechanism. The closed-loop control mechanism comprises a real-time blood glucose detection module, a temperature detection module, a blood glucose data processing module, a dose decision module, an injection pressure adjusting module, an injection channel control module, an insulin injection module and a closed-loop feedback module; noninvasive and high-sensitivity real-time blood glucose monitoring is achieved, the accuracy and timeliness of insulin administration are improved through trend prediction and individualized dose decision, meanwhile, multi-nozzle array piezoelectric needleless injection is combined with temperature compensation pressure regulation and a closed loop feedback correction mechanism, local tissue burden is effectively reduced, and the insulin administration efficiency is improved. And through multiple safety protection and wireless data transmission, remote monitoring and intelligent management are realized, so that the convenience, accuracy and reliability of blood glucose management of diabetic patients are greatly improved.

DISPLAY SCREEN WITH A GRAPHICAL USER INTERFACE FOR GLUCOSE MANAGEMENT

The present application relates to a blood sugar management system for pregnancy, comprising terminal devices carried by target users and reference users and a cloud server in data connection with the terminal devices, the cloud server being configured to: acquire physiological data and blood sugar data of the target users from the terminal devices, and calculate characteristic indexes of the target users based on the physiological data and the blood sugar data; acquire a plurality of blood sugar data of the reference users from the terminal devices and form an overall reference data set in a manner associated with gestational weeks, and assign the target users to a predetermined characteristic index value interval in the overall reference data set based on the characteristic indexes, so as to provide personalized health management suggestions for the target users based on factors identified to affect the risk of gestational diabetes mellitus of the target users.

The invention discloses a blood glucose management system used in a hospital, which comprises at least one blood glucose monitoring device comprising a sensor and an emitter, the sensor is used for monitoring blood glucose data of a patient in real time, and the emitter is used for at least emitting blood glucose data information; a plurality of receivers, wherein any one of the plurality of receivers can be used for receiving and transferring the information transmitted by the transmitter; the central server comprises a memory and a communication interface and is used for communicating with external equipment and storing information from the external equipment; and the medical personnel use end equipment is used for communicating with the central server and displaying or checking the blood glucose data information. Due to the fact that any one of the receivers can receive the blood glucose data monitored by the blood glucose monitoring device and upload the blood glucose data to the central server, the activity range of a patient in a hospital is not limited any more, and meanwhile medical staff can conveniently know the blood glucose level of the patient in time and in real time.

A blood glucose management system is disclosed, comprising a user terminal configured to capture an image of food, a processor, and an information providing device configured to provide the processor with blood glucose time-series information of a user prior to ingestion of the food. The processor is configured to execute a step of generating blood glucose trend prediction information of the user after ingestion of the food, based on data related to the food captured by the user terminal and the blood glucose time-series information. The user terminal is configured to display the blood glucose trend prediction information.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The application discloses a preparation method of starch-unsaturated fatty acid compound. The method comprises the following steps: starch is pretreated by a debranching enzyme to obtain a debranched starch solution, the debranched starch solution is mixed with unsaturated fatty acid, an ethanol-water solution is added as a ball milling medium, a multi-stage ball milling parameter dynamic regulation process is adopted, and low-temperature protection, medium-temperature complexing and cooling solidification stage ball milling reactions are sequentially carried out, and finally, drying, crushing and sieving are performed to obtain the starch-unsaturated fatty acid compound. Through the synergistic effect of debranching enzyme pretreatment and multi-stage ball milling, the starch and the unsaturated fatty acid are efficiently compounded under mild conditions. The obtained compound has high compounding rate, high resistant starch content and excellent antioxidant stability. The compound can be used as a low-glycemic index functional food raw material and is used for preparing blood glucose management, weight control or antioxidant functional food. The method is mild, controllable and reproducible, does not need high temperature and high pressure, and meets the clean label consumption trend.

The present application relates to a kind of based on blood glucose biosensor pregnancy auxiliary system, belong to medical management technical field, especially, it is related to the extended application of biosensor.The system includes: a plurality of user terminals, for obtaining the data information related to user pregnancy, including the blood glucose data obtained based on blood glucose biosensor and the basic information entered;With the communication connection of user terminal server, wherein, the shared database of server construction can be divided into several subgroups based on the preset group division rule, so that each user can be based on its basic information and correspond to one subgroup in the server, the processed blood glucose data obtained by user in current gestation period can be compared with the processed blood glucose data obtained by other users in the same gestation period in corresponding subgroup, to analyze the current blood glucose management of the patient by determining the ranking way, wherein, server can determine the preset group division rule based on the category of basic information.

This invention relates to the field of clinical medical and nursing device technology, specifically to an auxiliary turntable for blood glucose management and insulin dose adjustment in critically ill patients. It includes a base and a recommendation component. A support column is fixedly connected to the top of the base. The recommendation component includes a recommendation disc fitted outside the support column. A judgment component, including a judgment disc fitted outside the support column, is fitted outside the support column and is located on top of the recommendation cover. An identification component, including an identification disc fitted outside the support column, is fitted outside the support column. A base component, including a base disc fitted outside the support column, is located on top of the identification cover. Through the base, support column, and four sets of adjustment components, standardized and visual matching of multiple blood glucose indicators and insulin adjustment recommendations is achieved. Combined with three-color risk label strips, it quickly identifies abnormal blood glucose levels and fluctuation risks, enabling early detection and intervention, and reducing dose adjustment errors due to experience.

The application relates to the field of medical health data processing, and specifically provides a personalized insulin dose recommendation method and device for a diabetes patient, which has the following steps: S1, multi-source data preprocessing: collecting real-time dynamic data and static personalized parameters of the patient, performing outlier elimination, missing value completion, timestamp alignment and feature standardization processing on the data, and generating a time sequence matrix for input of an adaptive model; S2, constructing and training an LSTM-GRU blood glucose prediction model; S3, constructing and training a reinforcement learning dose decision model; and S4, closed-loop optimization and dose recommendation. Compared with the prior art, the application can significantly improve the accuracy and personalization degree of insulin dose recommendation, and provides reliable technical support for precise blood glucose management of the diabetes patient.

The fluid conveying equipment comprises a medicine storage device, a rotating sleeve, a ratchet wheel, a ratchet wheel transmission part and a power assembly, and a piston rod of the medicine storage device is sleeved with the rotating sleeve in a threaded connection mode; the ratchet wheel is mounted on the rotating sleeve in a circumferential limiting manner; the ratchet wheel transmission part is elastically clamped on the tooth surface of the ratchet wheel; the power assembly is in transmission connection with the ratchet transmission part; wherein the power assembly has a first working mode and a second working mode for continuous operation, and in the first working mode, the power assembly drives the ratchet wheel transmission part to perform first movement and is in linkage with the ratchet wheel to rotate by a first angle in the preset direction; in the second working mode, the power assembly drives the ratchet wheel transmission part to conduct second movement and is in linkage with the ratchet wheel to rotate by a second angle in the preset direction. In this way, the structure of the fluid conveying equipment can be simplified, the size is reduced, and the control precision and reliability of the fluid conveying equipment during working are improved.

This invention relates to healthcare information processing technology and discloses an intelligent blood glucose management system for early warning and intervention of gestational diabetes mellitus. The system includes a data acquisition unit, a parameter mapping unit, and a state prediction unit. The data acquisition unit acquires gene polymorphism characteristic parameters and a continuous real-time blood glucose monitoring signal stream. The parameter mapping unit maps the characteristic parameters to the initial state transition matrix of the blood glucose prediction model and determines the process noise covariance matrix. The state prediction unit generates a blood glucose prediction trajectory, calculates the sliding variance of the residual sequence, and triggers covariance adaptive adjustment logic when the sliding variance continuously exceeds a preset threshold. By increasing the diagonal elements of the noise covariance matrix, the blood glucose prediction trajectory is corrected. This invention utilizes a statistically driven adaptive adjustment mechanism to effectively map the nonlinear evolution of the mother's physiological state, eliminate the mismatch between genetic priors and real-time monitoring data, and suppress false positive alarms.

1.The name of the design product: graphical user interface of a diabetes child blood glucose management system of an electronic device. 2.The use of the design product: the design product is an electronic device. 3.The design points of the design product: the interface content of the graphical user interface in the screen. 4.The picture or photo that best indicates the design points: interface change state diagram 1. 5.The electronic device is a conventional design, and the rear view, left view, right view, top view, and bottom view are omitted. 6.The use of the graphical user interface: the design product is used to provide child diabetes management services for users. 7.The human-computer interaction mode of the graphical user interface: after entering the mobile phone number, password, and verification code in the main view, clicking the “login” button, displaying interface change state diagram 1; clicking the “custom AI recipe” button in interface change state diagram 1, displaying interface change state diagram 2; clicking the corresponding recipe picture in interface change state diagram 2, displaying interface change state diagram 3.

The application relates to a cooking control method, a cooking control device and an automatic cooking equipment, and belongs to the technical field of cooking control. The method is applied to the automatic cooking equipment and comprises the following steps: acquiring real-time blood glucose data collected by a continuous blood glucose monitoring device; based on the real-time blood glucose data, adjusting a cooking parameter of the automatic cooking equipment from a preset cooking parameter to a first cooking parameter; determining a predicted blood glucose change rate and an actual blood glucose change rate of the real-time blood glucose data; in response to an error between the actual blood glucose change rate and the predicted blood glucose change rate corresponding to the same time period exceeding a preset threshold, adjusting the cooking parameter of the automatic cooking equipment from the first cooking parameter to a second cooking parameter based on the error. The above method can automatically adjust the cooking parameter according to the real-time blood glucose data of a user and the blood glucose change rate of the real-time blood glucose data, accurately control the glycemic index of cooked food, adapt to the blood glucose condition of the user, and meet the blood glucose management demand of the user.

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

The invention discloses a blood glucose management system which is characterized in that when a patient operates and establishes communication connection, at least one of a detection module, an infusion module and a program module serves as signal source equipment to send low-power broadcast signals, and at least one of the equipment serves as equipment to be paired and establish communication connection; a patient operates the to-be-paired communication connection establishment device to approach the signal source device, when the to-be-paired communication connection establishment device enters the effective range of the broadcast signal, the broadcast signal can be searched, and the to-be-paired communication connection establishment device is paired with the signal source device to establish communication connection; the range is generally smaller than the conventional distance between the two devices, the situation that wrong communication connection is established due to the fact that the to-be-paired communication connection establishing device searches wrong broadcast signals can be avoided, a patient can automatically establish communication connection with the signal source device without inputting a device code, time and labor are saved, and the patient experience is improved. And the use experience of the patient is improved.

Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in a monitoring module and / or an infusion module; during a period when the monitoring module and / or the infusion module is powered on and sends a broadcast signal to the outside, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal and the preset signal strength threshold carried therein; when the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and / or the infusion module that sends the broadcast signal, without requiring the input of a device identifier of the monitoring module and / or the infusion module. Thus, the reliability of establishing a wireless communication connection between the program module and the patient's own monitoring module and / or infusion module is ensured.

A blood glucose management system is disclosed that incorporates a blood glucose prediction model configured to predict future blood glucose measurements of a person, such as a person with diabetes, on the basis of historical blood glucose measurements, insulin bolus dosage data, and carbohydrate intake data. The historical data are pre-processed to obtain a set of features that are advantageous for predicting future blood glucose measurements using the blood glucose prediction model. The predicted future blood glucose measurements enable the blood glucose management system to provide easy-to-understand visualizations of health information. The predicted future blood glucose measurements also enable the blood glucose management system to provide early warnings of a hypoglycemic condition or hyperglycemic condition of the person.

Methods and systems for encouraging interactions with a glucose monitoring system include incrementing a score and / or providing a reward based on a variety of different interactions with the glucose monitoring system. The interactions which improve the score may include initiating or changing displays, downloading data, setting operational parameters and other interactions that are independent of a user's glucose measurements. Encouraging these interactions can enhance success in maintaining healthy glucose concentrations.

Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in the blood glucose management system. During a period when a monitoring module and / or an infusion module is powered on and sends a broadcast signal, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal. When the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and / or the infusion module that sends the broadcast signal, without the need to input a device identifier of the monitoring module and / or the infusion module. Moreover, since the broadcast signal identified by the program module is sufficiently strong, it means that the program module is in proximity to the monitoring module and / or the infusion module that sends the broadcast signal, thereby ensuring the reliability of the program module establishing a wireless communication connection with a patient's own monitoring module and / or infusion module.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

This application relates to a device control method, an insulin infusion device, and a storage medium. The method is applied to an insulin infusion device, which includes a drive mechanism and a dispensing mechanism. The device control method includes: determining the current operating mode of the insulin infusion device; and in the current operating mode, when a user's current input to a function icon is detected, determining whether the current input is a prohibited operation according to the safety operating rules of the current operating mode; if the current input is a prohibited operation, controlling the insulin infusion device not to respond to the current input; if the current input is not a prohibited operation, controlling the insulin infusion device to respond to the current input by executing a corresponding instruction to control the drive mechanism to push the dispensing mechanism, thereby realizing insulin infusion. This method can improve the safety of insulin infusion devices.

This invention belongs to the technical field of functional foods for blood glucose management, specifically relating to a postprandial blood glucose-suppressing composition containing inactivated Akkermansia myxophilus. Existing blood glucose control products have limited effectiveness or significant side effects. The composition of this invention contains inactivated Akkermansia myxophilus and blood glucose-lowering active ingredients such as mulberry leaf extract and chromium yeast. This invention achieves the effects of reducing postprandial blood glucose peaks and improving glucose metabolism through a dual mechanism of slowing carbohydrate absorption and improving insulin sensitivity. The composition of this invention is stable at room temperature and can be formulated into tablets or capsules.

This invention discloses a sports nutrition food for post-exercise recovery and blood glucose management. Each 40g portion contains Astragalus membranaceus extract, Dioscorea opposita extract, white kidney bean extract, mulberry leaf extract, L-arabinose, cinnamon extract, whey protein peptides, and a mineral-vitamin-probiotic premix. This invention utilizes a six-fold blood glucose control pathway through a four-mineral glucose control matrix, triple carbohydrate blocking, probiotics, and dual tonification of Qi and Yin with traditional Chinese medicine. Animal experiments showed that the fasting blood glucose level in the full-formula group decreased to 6.3 mmol / L, significantly better than the control group (*p*<0.05). All ingredients comply with national standards for sports nutrition foods and are safe and compliant.